Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 1/20 | 0.44 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | GMNN | O75496 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | CETP | P11597 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | CXCR5 | P32302 | 2/20 | 0.41 |
| ▸ | CCR6 | P51684 | 2/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.41 |
| ▸ | UBE2N | P61088 | 2/20 | 0.41 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23448634 | 0.91 | GRIK1 (0.42) | EP300SPHK1MEN1KMT2AMAPT | |
| SCHEMBL11973145 | 0.83 | EP300 (0.47) | EP300MEN1KMT2AMAPTGMNN | |
| SCHEMBL11973141 | 0.83 | EP300 (0.47) | EP300MEN1KMT2AMAPTGMNN | |
| SCHEMBL11973124 | 0.83 | EP300 (0.47) | EP300MEN1KMT2AMAPTGMNN | |
| SCHEMBL11973121 | 0.83 | EP300 (0.47) | EP300MEN1KMT2AMAPTGMNN | |
| SCHEMBL11973094 | 0.81 | EP300 (0.45) | EP300MEN1KMT2AMAPTGMNN | |
| SCHEMBL11973098 | 0.81 | EP300 (0.45) | EP300MEN1KMT2AMAPTGMNN | |
| SCHEMBL11973439 | 0.80 | EP300 (0.43) | EP300MEN1KMT2AMAPTGMNN | |
| SCHEMBL11973443 | 0.80 | EP300 (0.43) | EP300MEN1KMT2AMAPTGMNN | |
| SCHEMBL19093966 | 0.80 | MAPT (0.46) | EP300SPHK1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190016703-A1 | BIFUNCTIONAL COMPOUNDS FOR HER3 DEGRADATION AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2019-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190016703-A1 | BIFUNCTIONAL COMPOUNDS FOR HER3 DEGRADATION AND METHODS OF USE | MDM2, ERBB2, ITCH | EP300 1927/4885SPHK1 4415/4885MEN1 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.